Navigation Links
Haemonetics Provides Update on Hemerus Medical, LLC Acquisition
Date:9/17/2012

BRAINTREE, Mass., Sept. 17, 2012 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) today provided an update on the status of its previously announced agreement to acquire Hemerus Medical, LLC ("Hemerus"), a Minnesota-based company that develops innovative technologies for the collection of whole blood and for the processing and storage of blood components.  Hemerus' US New Drug Application and EU Medical Device Directive technical file for the SOLX® whole blood collection system had been submitted to the FDA and TUV SUD notified body, respectively.

(Logo: http://photos.prnewswire.com/prnh/20120206/NE47232LOGO )

Today the Company announced that it has learned that Hemerus has received a request from the FDA for resubmission of their application with additional information.  As a result, the timing of the closing of the acquisition, which is contingent upon receipt of FDA approval, is still pending and now is expected to occur early in fiscal 2014.  In addition, the Company has also learned that Hemerus has received CE Marking (Conformite Europeenne) in the European Union to market SOLX with the world's first 56-day red blood cell storage indication.  

Haemonetics' plans include delivery of its first whole blood automation software package, an automated whole blood collection device and continued development of acquired Pall whole blood products.  We believe SOLX remains an important part of the strategy for rapid market adoption of the whole blood product suite.  The FDA request for resubmission has minimal effect on our pipeline development since the inclusion of the SOLX solution in these products was contemplated for fiscal 2014 and beyond. 

Brian Concannon, President and CEO, stated: "The addition of Hemerus' SOLX collection system is intended to complement the portfolio of whole blood collection, filtration and processing product lines we recently acquired from Pall Corporation.  We will proceed with the Haemonetics and Pall elements of that offering while the FDA examination process for the SOLX solution continues.  We are pleased that CE Marking has been granted which gives credibility to the value of this new science."

Haemonetics paid $1 million cash in its first fiscal 2013 quarter and, upon receipt of the aforementioned FDA approvals for the product, will pay the remainder of the $27 million purchase price for Hemerus Medical.  Additionally, Haemonetics has agreed to pay a royalty of up to $14 million on future sales of SOLX-based products. 

Haemonetics is a global healthcare company dedicated to providing innovative blood management solutions for our customers.  Together, our devices and consumables, information technology platforms, and consulting services deliver a suite of business solutions to help our customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world.  Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services.  To learn more about Haemonetics, visit our web site at http://www.haemonetics.com.             

This release contains forward-looking statements that are not historical facts. Haemonetics has identified some of these forward-looking statements with words like "will," "expect," "intend," "believe," "may," "could," "would," "might," "possible," "plan," "anticipate," or "continue," the negative of these words, other terms of similar meaning or the use of future dates.  Forward-looking statements in this release include without limitation statements regarding the expected timing of the completion of the transaction and statements regarding the effect of the transaction on Haemonetics' business and competitive position, statements regarding future innovation and statements regarding Haemonetics' future financial performance and financial condition. Information set forth in this press release is current as of today and the Company undertakes no duty or obligation to update this information.

Investors and security holders are cautioned not to place undue reliance on these forward-looking statements.  These forward-looking statements are based on estimates and assumptions made by management of the Company and are believed to be reasonable, though inherently uncertain and difficult to predict. Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties, including: uncertainties as to the timing of the transaction; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the products discussed; the effects of disruption from the transaction making it more difficult to maintain relationships with employees, customers, vendors and other business partners; the risk that stockholder litigation in connection with the transaction may result in significant costs of defense, indemnification and liability; other business effects, including the effects of industry, economic or political conditions outside of Haemonetics' control; transaction costs; actual or contingent liabilities; and other risks and uncertainties discussed in Haemonetics' filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections of Haemonetics' most recent annual report on Form 10-K and quarterly reports on Form 10-Q.

SOLX® is a registered trademark of Hemerus Medical, LLC.

CONTACT:  
Gerry Gould, VP-Investor Relations  
Tel. (781) 356-9402   
gerry.gould@haemonetics.com   
Alt. (781) 356-9613  


'/>"/>
SOURCE Haemonetics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Haemonetics Completes Acquisition of Palls Transfusion Medicine Business
2. Haemonetics Signs Definitive Agreement to Acquire Pall Corporations Blood Collection, Filtration and Processing Product Lines For $551 Million
3. Haemonetics Signs Definitive Agreement To Acquire Hemerus Medical, LLC
4. CareFusion Provides Update On Form 10-K Filing
5. Ixonos Provides NHS Choices With Innovative Health Apps
6. Medical Alarm Provides Investor Update -- Company Surpassing Previous Record Order Levels as Consumer Interest Accelerates
7. Organovo Reports Q2 2012 Financial Results, Provides Business Update
8. Trovagene, Inc. Announces Second Quarter and Year to Date Earnings, Provides Milestone Update
9. Fulcrum Equity Partners Provides $5 Million in Growth Equity to Medical Direct Club
10. Unprecedented Study shows Berlin Heart device provides life-saving "bridge" for young children and babies
11. Alexza Reports 2012 Second Quarter Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017  Vivify Health, the pioneer ... has been awarded a very significant patent for the ... to continual care via digital health.  This landmark patent ... property and further secures Vivify,s position as the leader ... 2009, was the first company to apply consumer mobile ...
(Date:4/20/2017)... April 20, 2017 Research and Markets has ... Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage of ... ... delivery technologies will rise from USD 20 Billion in 2015 to ... Drug Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market ...
(Date:4/20/2017)... Research and Markets has announced the ... Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies ... ... was valued at US$ 7,167.6 Mn in 2015, and is ... a CAGR of 5.6% from 2016 to 2024. ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... April 24, 2017 , ... ... prescription opioid overdose deaths now claim the lives of 62 Americans each day.(1) ... filings against drug manufacturers, distributors, pharmacies and prescribers by more than half.(2) ...
(Date:4/24/2017)... , ... April 24, 2017 , ... ... designed to recognize elevated anxiety levels in people with addiction who are served ... Smart Patch, a biosensing wearable device that monitors heart and breath rates to ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... health of individuals with HIV because it is not known to have significant ... have favorable effects to both lower cholesterol levels and dampen inflammation in the ...
(Date:4/24/2017)... ... ... Come to PAINWeekEnd (PWE) Tampa on May 20 and 21, at the ... 2-day program. , An attendee at a recent PAINWeekEnd said, "Very helpful, wish ... course entitled Ain't Misbehavin': Decreasing and Managing Pain Patient Aberrant Behavior, presented by Dr. ...
(Date:4/24/2017)... FOREST KNOLLS, Calif. (PRWEB) , ... April 24, 2017 , ... ... and health topics, but she has not found any of them to be very ... weekly actions to slowly and easily make changes in their health. It prompted her ...
Breaking Medicine News(10 mins):